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Mitochondria do not exist as discrete static entities; rather, mitochondria form a network that continuously
moves, divides, and fuses. The structure of this dynamic network is in part maintained by a balance of division
and fusion events (Hoppins et al., 2007). The ratio of division to fusion events that defines a proper balance is
not universal but varies with developmental stage, cell type, and biological circumstances. This is evident
throughout the cell cycle in higher eukaryotes, where mitochondria elongate during the G1/S transition
and fragment at the onset of mitosis, and when mitochondria fragment in response to certain cellular stimuli,
such as increases in cytosolic calcium levels (Breckenridge et al., 2003; Cereghetti et al., 2008; Han et al.,
2008; Mitra et al., 2009; Taguchi et al., 2007). The functional state and distribution of mitochondria are clearly
influenced by its steady-state structure. When the normal balance of division and fusion is disrupted as
a consequence of the inappropriate stimulation or inhibition of either process, problems arise at the cellular
level that compromises the well-being of the organism as a whole. This is evident by the ever-increasing
number of diseases in which abnormal mitochondrial dynamics have been etiologically implicated. In this
context, the mitochondrial division and fusion machines are valuable and interesting targets of small mole-
cule effectors, as inhibition or activation of these processes may be able to restore the proper dynamic
balance and function. A small molecule inhibitor of mitochondrial division, mdivi-1, has already been identi-
fied and characterized (Cassidy-Stone et al., 2008). This inhibitor has provided valuable insight into themech-
anism of mitochondrial division and has shown great therapeutic promise in a wide array of disease models.
This review will focus on small molecule effectors of mitochondrial division, discussing their value in basic
biological research as well as their therapeutic potential.Mitochondrial Dynamics in Healthy and Disease States:
A Case for Identifying Small Molecule Inhibitors
of Mitochondrial Division
Mitochondrial division and fusion are antagonistic activities
whose fundamental roles are to create a compartment that is
a connected conductor, able tomix its contents and have access
to mtDNA and its products, but able to be distributed to distant
cellular destinations via transport on actin or microtubule
networks. Inboth yeast andhigher eukaryotes, disruptionofmito-
chondrial division leads to an extensively interconnected and
collapsed mitochondrial network that leaves many areas of the
cell devoid of the organelle. In contrast, defects in mitochondrial
fusion cause extensive mitochondrial fragmentation and
acompleteor partial lossofmtDNA in yeast andmammaliancells,
respectively (Hoppins et al., 2007). Disrupting division and fusion
in yeast is not a lethal event. In contrast, the effects of disrupted
division and fusion in higher eukaryotes are much more adverse
to the organism. Mice lacking the dynamin related proteins
(DRPs) that comprise the heart of mitochondrial division and
fusionmachines,Drp1andMFN1/2orOPA1, respectively, exhibit
deleterious developmental defects (Chen et al., 2003; Davies
et al., 2007; Ishihara et al., 2009;Wakabayashi et al., 2009).Muta-
tions in humanDrp1 cause early infant mortality, andmutations in
MFN2 and OPA1 cause two distinct types of neurodegenerative
diseases, Charcot Marie Tooth 2A (CMT2A) and dominant optic578 Chemistry & Biology 17, June 25, 2010 ª2010 Elsevier Ltd All rigatrophy (DOA), underscoring theessential natureofmitochondrial
dynamics in higher eukaryotes (Alexander et al., 2000; Delettre
et al., 2000; Waterham et al., 2007; Zuchner et al., 2006).
Improper mitochondrial distribution and morphology, as a
result of attenuated division and fusion, are likely to be major
causes of many adverse effects. However, the disruption of
mitochondrial dynamics also has negative effects on mitochon-
drial function that are not as easily explained by changes in the
overall steady-state structure or content mixing of the organelle.
In cells that lack MFN2 or express CMT2A-associated disease
alleles of MFN2, axonal transport of mitochondria is disrupted
(Baloh et al., 2007); Interestingly, this disruption in transport
does not appear to be a consequence of attenuated fusion, sug-
gesting a fusion-independent role for MFN2 in the regulation
of mitochondrial motility (Misko et al., 2010). In the absence of
ongoing mitochondrial division, general mitochondrial dysfunc-
tion, such as loss of membrane potential, increase in ROS,
increase in oxidized proteins, and loss of mitochondrial DNA,
are observed (Lee et al., 2007; Parone et al., 2008; Twig et al.,
2008; Yoon et al., 2006). These sublethal stresses induce senes-
cence-associated phenotypic changes in cells, highlighting the
intimate connection between mitochondrial function and cellular
function (Lee et al., 2007; Yoon et al., 2006).
Mitochondrial dynamicshavealsobeenproposed toplay a role












Figure 1. Modulation of Drp1-Mediated Mitochondrial Division
and Potentiation of Apoptosis by Negative and Positive Effectors
Negative effectors may block Drp1 assembly, as is the case for mdivi-1, or
other critical aspects of Drp1 function and thus attenuate mitochondrial divi-
sion and/or mitochondrial outer membrane permeabilization (MOMP). Positive
effectors may stimulate Drp1 assembly and/or function and, depending on the
distinct set of effectors, which are likely defined by biological circumstances,
mitochondrial division and/or MOMP can be stimulated.
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chondria with different membrane potentials can be produced.
The functional daughter, which retains a high membrane poten-
tial, can refusewith themitochondrial network,while thedysfunc-
tional daughter cannot refuse due to lowmembrane potential and
is subsequently flagged for autophagic degradation (Parone
et al., 2008; Twig et al., 2008). This is consistent with recent
work on the Pink1/Parkin pathway, which demonstrates that
the selective Pink1-dependent recruitment of Parkin, anE3-ubiq-
uitin ligase, tomitochondriawith low-membrane potential targets
the damaged organelles for degradation (Matsuda et al., 2010;
Narendra et al., 2008; Narendra et al., 2010). Thus, it is possible
that the increase in dysfunctional mitochondria in the absence
of divisionmaybedue to the loss of a role for division in thequality
control of the mitochondrial compartment.
Current data suggest that Drp1 also plays an independent role
in the regulation of intrinsic apoptosis, specifically via the control
of outer membrane permeabilization by the pro-apoptotic
Bcl2 protein, Bax (Figure 1). Concomitant with mitochondrial
outer membrane permeabilization during apoptosis, Drp1 self-
assembly and its recruitment to mitochondria are increased,
resulting in an enhanced rate of Drp1-dependent mitochondrial
division and mitochondrial fragmentation (Breckenridge et al.,
2003; Frank et al., 2001; Wasiak et al., 2007). Inhibition of
Drp1-dependent mitochondrial division delays and partially
inhibits apoptosis, suggesting a functional link between the
progression of apoptosis and Drp1-mediated mitochondrial
fragmentation. Mitochondrial fusion also plays a role in the regu-
lation of apoptosis (Frank et al., 2001; Jagasia et al., 2005; Lee
et al., 2004). In contrast to Drp1, MFN1 and MFN2 are thoughtChemistry & Bito play a protective role against apoptosis in cells as the inhibi-
tion of fusion makes cells more sensitive to apoptotic stimuli.
Given the importance of mitochondrial dynamics for cellular
function, regulation, and cell death, it is perhaps not surprising
that aberrant mitochondrial dynamics/morphology have been
associated with numerous and prevalent human diseases,
including Alzheimer’s disease, Parkinson’s disease, Hunting-
ton’s disease, amyotrophic lateral sclerosis, and diabetes (Poole
et al., 2008; Wang et al., 2009; Zorzano et al., 2009). In these
cases, fragmentation of the mitochondrial network has been
observed in disease patient samples and/or in cell culture
disease models, suggesting a shift in the division/fusion balance
toward division. The cause of the shift in each case is unclear and
could be a result of direct activation of mitochondrial division,
direct inhibition of mitochondrial fusion, or both, or as an indirect
result of cellular stress, which can affect the division/fusion
balance. In the cases of themitochondrial fusion-linked diseases
DOA and CMT2A, it is clear that the disease-associated mito-
chondrial morphologies are at least in part due to a direct
shift toward division as a result of attenuated fusion. The link
between increased mitochondrial division and disease states,
and between mitochondrial division and apoptosis makes the
mitochondrial division machine an attractive target for therapeu-
tics that could treat an impressive array of diseases from neuro-
degeneration to more acute conditions, such as stroke, myocar-
dial infarction, and drug toxicity.
The Mitochondrial Division Machine: A Deep Target
for Small Molecule Effectors
The heart of the mitochondrial division machine is the dynamin-
related GTPase Dnm1 (yeast)/Drp1 (mammals). While cytolog-
ical analysis, which places Dnm1/Drp1 at sites of mitochondrial
division, provides compelling support for the role of Dnm1/Drp1
as the master regulator of mitochondrial division, biochemical
and structural analyses of the yeast mitochondrial division dyna-
min have provided the insight needed for a mechanistic under-
standing of how Dnm1/Drp1 does the work of mitochondrial
division (Ingerman et al., 2005; Legesse-Miller et al., 2003; Naylor
et al., 2006; Sesaki and Jensen, 1999). These analyses have sug-
gested a model in which GTP binding to Dnm1 dimers produces
conformational changes that facilitate the assembly of Dnm1 into
helical structures (Ingerman et al., 2005). These helical structures
possess diameters that match the diameters of mitochondrial
constriction sites in vivo, indicating that Dnm1 self-assembly
drives mitochondrial constriction (Figure 1). Dnm1 self-assembly
also stimulates GTP hydrolysis, which is required for mitochon-
drial division, likely by producing additional structural changes
in the Dnm1 helix and by promoting disassembly (Ingerman
et al., 2005; Naylor et al., 2006). Interestingly, Dnm1 self-
assembly proceeds via a rate-limiting, Dnm1 concentration-
dependent nucleation event, whichmay be exploited as ameans
to regulate the assembly and thus the function of Dnm1 in vivo
(Ingerman et al., 2005).
The mammalian mitochondrial division dynamin Drp1 also
assembles into helical structures that can tubulate liposomes
in vitro, albeit with smaller diameters than those formed by
Dnm1, and thus likely functions via a similar mechanism
(Smirnova et al., 2001; Yoon et al., 2001). While the basic mech-
anism of membrane division is likely conserved, regulation ofology 17, June 25, 2010 ª2010 Elsevier Ltd All rights reserved 579
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Drp1 self-assembly and/or assembly associated conformational
changes have been harnessed in mammalian cells to integrate
mitochondrial division with cellular physiology. This is evident
when comparing the steady-state cellular distributions of the
two proteins. In contrast to Dnm1, which predominantly exists
in assembled structures, Drp1 is mainly distributed in a diffuse
manner throughout the cytosol in cultured cells, which suggests
that it is predominantly unassembled (Labrousse et al., 1999;
Otsuga et al., 1998; Sesaki and Jensen, 1999; Smirnova et al.,
2001). However, in response to certain cellular stimuli such as
increases in cytosolic calcium levels or the initiation of apoptosis,
mitochondrial targeting and assembly of Drp1 is greatly
enhanced and consequently mitochondrial division is increased
(Breckenridge et al., 2003; Frank et al., 2001; Germain et al.,
2005). While the mechanisms underlying the regulation of Drp1
assembly are unclear, it is still evident that the regulation of
assembly can be used as a means to regulate function.
Although DRPs are the heart of the division machine, mito-
chondrial division is strictly dependent on additional non-DRP
factors. The roles of these factors are best characterized in
yeast, where it is clear that two additional proteins, Fis1 and
Mdv1, are essential for Dnm1-mediated mitochondrial division
(Cerveny et al., 2001; Fekkes et al., 2000; Mozdy et al., 2000;
Tieu and Nunnari, 2000). Fis1 is anchored to the mitochondrial
outer membrane via a C-terminal transmembrane domain. The
N terminus of the protein is exposed to the cytosol and interacts
directly with Mdv1 (Dohm et al., 2004; Karren et al., 2005; Mozdy
et al., 2000; Suzuki et al., 2003, 2005; Tieu and Nunnari, 2000;
Tieu et al., 2002). Mdv1 functions as a molecular bridge between
mitochondrial-anchored Fis1 and soluble Dnm1, and together
Fis1 and Mdv1 function to target Dnm1 to the mitochondrial
surface (Griffin et al., 2005; Karren et al., 2005; Tieu and Nunnari,
2000; Tieu et al., 2002). Recent work has demonstrated that
Mdv1 also functions posttargeting to nucleate the assembly of
Dnm1 on the mitochondrial surface. Indeed, biochemical and
cytological evidence suggests that the native yeast division
machine is a structure comprised of coassembled Dnm1 and
Mdv1 (Lackner et al., 2009). Two additional Dnm1-interacting
proteins, Caf4, which is an Mdv1 paralog, and Num1, which is
a coiled-coil protein localized to the cell cortex, have been iden-
tified but are not essential for division (Cerveny et al., 2007;
Griffin et al., 2005). How these proteins act together combinato-
rially with Fis1 and Mdv1 to modulate division and potentially
other processes in the cell will provide additional insight into
the regulation and functions of the division DRP.
In mammalian cells, several non-DRP proteins have been
identified as important regulators of mitochondrial division;
however, their precise functions have not yet been determined.
For example, a mammalian Fis1 ortholog has been identified
and likely plays a role in division, but it is not essential for Drp1
targeting, suggesting that additional pathways for Drp1 activa-
tion have evolved in mammalian cells (Lee et al., 2004; Stojanov-
ski et al., 2004; Suzuki et al., 2003). Indeed, a structural or
functional ortholog of Mdv1 has not yet been identified in higher
eukaryotes. Given that division is more integrated and regulated
in mammalian cells, it seems likely that Mdv1 has been replaced
by several adaptor and/or nucleator type components that per-
form similar essential functions in division, but may be present580 Chemistry & Biology 17, June 25, 2010 ª2010 Elsevier Ltd All rigin a cell type-specific manner and/or respond to different cellular
signaling pathways (Lackner and Nunnari, 2008). Candidates for
Drp1 effectors in mammalian cells include the mitochondrial
outer membrane proteins, hFis1, Mff, and GDAP1 (ganglioside-
induced differentiation associated protein 1), which when
mutated causes CMT, the inner membrane space protein
MTP18 and the BAR domain protein, Endophilin B1 (Gandre-
Babbe and van der Bliek, 2008; Karbowski et al., 2004; Lee
et al., 2004; Niemann et al., 2005; Stojanovski et al., 2004; Suzuki
et al., 2003; Tondera et al., 2005, 2004). Also, during apoptosis,
both Bax and Drp1 translocate to the mitochondrial outer
membrane and colocalize in foci on mitochondria, suggesting
that Bax and potentially other Bcl2 family member proteins
also function as effectors of Drp1 activity, as suggested by the
finding that Bcl-xL overexpression positively regulates Drp1 to
stimulate synapse formation (Karbowski et al., 2002; Li et al.,
2008). In addition to these potential protein regulators of mito-
chondrial division, the function of Drp1 is also influenced by
posttranslational modification. Phosphorylation, nitrosylation,
ubiquitination, and sumolyation have all been identified as post-
translational modifications that can positively or negatively affect
the function of Drp1 (Cereghetti et al., 2008; Chang and Black-
stone, 2007; Cho et al., 2009; Cribbs and Strack, 2007; Han
et al., 2008; Harder et al., 2004; Nakamura et al., 2006; Taguchi
et al., 2007; Yonashiro et al., 2006; Zunino et al., 2007). It is likely
that a distinct combination of protein effectors and posttransla-
tional modifications regulate the activity of Drp1 in different
physiological contexts (Figure 1).
While the mitochondrial division machine is comprised of and
influenced by many factors, the mitochondrial division dynamins
Dnm1 and Drp1 are the most obvious targets of small molecule
modulators of division. They are the highly conserved, core
mechanical component of the division machine and are the
best understood mechanistically. In addition, the division DRP
is a deep target for small molecule effectors, since there are
many functionally critical features of the protein, such as GTP
binding, GTP hydrolysis, and self-assembly, which is mediated
by conformational changes linked to the GTPase cycle. There-
fore, small molecule effectors that target different functional
facets of Dnm1/Drp1 and thus either positively or negatively
affect distinct stages of Dnm1/Drp1-driven mitochondrial divi-
sion can be identified. Finally, given the increasing number of
Drp1-interacting proteins that have been implicated in division,
it may be possible to identify tissue-specific or context-specific
inhibitors ofmitochondrial division by identifying small molecules
that target and modulate Drp1-effector interactions.
Mdivi-1: The First Inhibitor of the Mitochondrial Division
DRP
Using a simple growth-based assay in yeast, the first small
molecule effector of the mitochondrial division DRP, Dnm1,
was identified and was demonstrated to also target Drp1 in
mammalian cells (Cassidy-Stone et al., 2008), speaking to the
conserved primary mechanism of mitochondrial division. Mech-
anistically, mdivi-1 acts as amixed type inhibitor to attenuate the
early stages of division DRP assembly by preventing the poly-
merization of higher order structures. Mdivi-1 selectively targets
the unassembled pool of the mitochondrial division dynamin,
and its binding creates and/or stabilizes an assembly-deficienthts reserved
Table 1. The Therapeutic Potential of Genetic and Chemical Inhibition of Mitochondrial Division
Disease/Injury Effects of inhibited mitochondrial division Method of inhibition References
Parkinson’s disease Attenuation of the adverse effects Pink1 and
Parkin mutants have on mitochondrial function
and morphology in PD disease models
Genetic and chemical Lutz et al., 2009
Cui et al., 2010
Alzheimer’s disease Attenuation of b-amyloid protein- or nitric
oxide-induced mitochondrial fragmentation
and neuronal cell damage
Genetic Barsoum et al., 2006
Cho et al., 2009
Huntington’s disease Attenuation of the adverse effects of Htt mutations
on mitochondrial function and morphology
Genetic Wang et al., 2009
Ischemia/reperfusion injury Protection against cardiac injury in a murine
model of ischemia/reperfusion
Genetic and chemical Ong et al., 2010
Protection against renal injury in a rodent
model of inschemia/reperfusion
Genetic and chemical Brooks et al., 2009
Drug toxicity-induced tissue damage Protection against cisplatin-induced renal damage Genetic and chemical Brooks et al., 2009
Chemistry & Biology
Minireviewconformation (Figure 1). Assembly of the division DRP is critical
for function; thus, mdivi-1 acts as an efficacious inhibitor of mito-
chondrial division in cells. Given the conservation of the DRP
super family members, it is remarkable that mdivi-1 also displays
a high degree of selectively for the mitochondrial division dyna-
mins. It has no effect on other DRPs, such as the endocytic dy-
namin or the mitochondrial fusion dynamins. This selectivity is
encouraging for the division dynamin as a therapeutic target
(see below). Systems are in place to screen for additional small
molecule effectors of the mitochondrial division dynamin, as
both cellular and biochemical assays of Dnm1/Drp1 activity
and function are well established. In addition, these assays can
be used, as theywere for mdivi-1, to precisely identify the cellular
and biochemical activities of the division DRP.
The identification of mdivi-1 and other likely inhibitors of the
mitochondrial division dynamin have and will continue to prove
beneficial in dissecting the exact roles mitochondrial division,
or Drp1 specifically, plays in the maintenance of proper cellular
function. These small molecule effectors can extend the resolu-
tion of genetic, cytological, and biochemical approaches by
allowing discrete steps in mitochondrial division or Drp1 activi-
ties to be modulated selectively, rapidly, and reversibly. This
modulation can occur in an otherwise wild-type background
without the need for the generation of mutant or knockout cell
lines or the depletion of protein levels by techniques such as
RNAi. Thus, complications from second site suppressors or indi-
rect effects can be reduced. In addition, the effects of increased
or decreased Drp1 activity can be monitored immediately. Thus,
the evolution of the cellular defects associated with loss of
Drp1 activity can be tracked over time, providing a clearer
picture of the primary and secondary consequences of aberrant
Drp1 function. Also, when used in combination with biochemical
assays, biochemical activity can be correlated with cellular
function. Indeed, mdivi-1 has already proven to be useful as
a tool to identify the role of Drp1 in intrinsic apoptosis. Specifi-
cally, in cell-free MOMP assays where mitochondrial division
does not occur, mdivi-1 blocks cytochrome-c release (Cassidy-
Stone et al., 2008). Thus, Drp1 has a positive regulatory role in
MOMP that is independent of its role in mitochondrial division,
demonstrating that Drp1 possesses multiple independent roles
in mammalian cells (Figure 1). In addition, the use of mdivi-1Chemistry & Bifor the acute inhibition of Drp1 activity in cultured mammalian
cells has revealed a regulatory role for a hyperfused mitochon-
drial state in the regulation of cyclin E levels and consequently
in cell cycle progression (Mitra et al., 2009).
The Therapeutic Potential of Small Molecule Effectors
of Mitochondrial Division: Putting mdivi-1 to the Test
While the etiology of many diseases in which aberrant mito-
chondrial morphology is observed is uncertain, inhibiting mito-
chondrial division with mdivi-1 in Parkinson’s disease cell culture
models or a dominant negative form of Drp1 in Alzheimer’s and
Huntington’s disease cell culture models attenuates disease-
associated phenotypes (Barsoum et al., 2006; Cho et al., 2009;
Cui et al., 2010; Lutz et al., 2009; Wang et al., 2009) (Table 1).
These results demonstrate the therapeutic potential of small
molecule inhibitors of mitochondrial division to disease. The
role of Drp1 in the facilitation of apoptosis has also been ex-
ploited for its therapeutic potential (Table 1). The reperfusion of
ischemic cells as a result of events such as stroke or myocardial
infarction induces apoptotic cell death, which can lead to severe
tissue and organ damage. In these cases, small molecule inhib-
itors of Drp1 may serve to protect against apoptotic cell death
following such a temporary insult. Indeed, this approach seems
promising, as the therapeutic potential of Drp1 inhibition using
genetic approaches and also with mdivi-1 has now been tested
with good success in experimental models of cardiac and renal
ischemia/reperfusion (Brooks et al., 2009; Ong et al., 2010). In
addition, it has been shown that mdivi-1 is efficacious in rodent
models of cisplatin-induced renal damage, also a result of
apoptotic cell death (Brooks et al., 2009). Thus inhibitors of
Drp1 have potential therapeutic application for a wider array of
drug toxicity-induced tissue damage.
Although not yet put to the test, it seems likely that mdivi-1 or
other inhibitors of mitochondrial division will prove beneficial
to the mitochondrial fusion-linked neuropathies CMT2A and
DOA, where the detrimental effects of ongoing division in the
absence or attenuation of mitochondrial fusion are clearly evi-
dent (Alexander et al., 2000; Delettre et al., 2000; Kijima et al.,
2005). Interestingly, recent work has shown that partial restora-
tion of mitochondrial fusion in mammalian cells can rescue the
longer term defects associated with loss of fusion: decreasedology 17, June 25, 2010 ª2010 Elsevier Ltd All rights reserved 581
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rates of mtDNA mutation (Chen et al., 2005, 2010). Thus, small
molecule inhibitors of mitochondrial division, which can serve
to restore the connectivity of the mitochondrial network, may
also rescue the defects associated with loss/attenuation of
fusion. Inhibitors of Drp1 are also logical potential therapeutics
in cases of human diseases caused by heteroplasmic mtDNA
mutations. Inhibition of mitochondrial division would increase
connectivity of mitochondria and enhance access to wild-type
products of mtDNA genes to allow for complementation of respi-
ratory or other dysfunction. It is important to note, however, that
mitochondrial division is an essential event in cells (Ishihara et al.,
2009; Wakabayashi et al., 2009; Waterham et al., 2007). Indeed,
stimulation of mitochondrial division enhances mitochondrial
mass and distribution in neurons and stimulates synapse forma-
tion (Li et al., 2008). Mitochondrial divisionmay also be an essen-
tial event for mitochondrial quality control. In this context, the
mechanism of mdivi-1 inhibition is advantageous as it can act
much like a dimmer switch on a light bulb, to cause increasing
degrees of mitochondrial connectivity, which provide for efficacy
while allowing for distribution and other Drp1 related functions.
Finally, although not yet discovered, small molecule activators
of Drp1 and inhibitors ofmitochondrial fusion DRPs are attractive
as anti-cancer therapies as they have potential to stimulate
apoptotic cell death.
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